162 related articles for article (PubMed ID: 37857563)
1. Identification of the prognostic immune subtype in copy-number high endometrial cancer.
Mao M; Jiang F; Han R; Xiang Y
J Gynecol Oncol; 2024 Jan; 35(1):e8. PubMed ID: 37857563
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer.
Li BL; Wan XP
J Cell Mol Med; 2020 Jul; 24(14):7767-7777. PubMed ID: 32424934
[TBL] [Abstract][Full Text] [Related]
3. Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype.
Dessources K; Ferrando L; Zhou QC; Iasonos A; Abu-Rustum NR; Reis-Filho JS; Riaz N; Zamarin D; Weigelt B
Gynecol Oncol; 2023 Apr; 171():15-22. PubMed ID: 36804617
[TBL] [Abstract][Full Text] [Related]
4. Construction of an Immune-Autophagy Prognostic Model Based on ssGSEA Immune Scoring Algorithm Analysis and Prognostic Value Exploration of the Immune-Autophagy Gene in Endometrial Carcinoma (EC) Based on Bioinformatics.
Xu X; Lu F; Fang C; Liu S
J Healthc Eng; 2022; 2022():7832618. PubMed ID: 35242299
[TBL] [Abstract][Full Text] [Related]
5. Follicular Helper T-Cell-Based Classification of Endometrial Cancer Promotes Precise Checkpoint Immunotherapy and Provides Prognostic Stratification.
Chen Y; You S; Li J; Zhang Y; Kokaraki G; Epstein E; Carlson J; Huang WK; Haglund F
Front Immunol; 2021; 12():788959. PubMed ID: 35069566
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Five-immune Gene Pair Signature in Endometrial Carcinoma.
Li N; Yu K; Lin Z; Zeng D
Comb Chem High Throughput Screen; 2021; 24(2):233-245. PubMed ID: 32729416
[TBL] [Abstract][Full Text] [Related]
7. Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics.
Liwei L; He L; Yibo D; Luyang Z; Zhihui S; Nan K; Danhua S; Junzhu W; Zhiqi W; Jianliu W
World J Surg Oncol; 2023 Oct; 21(1):332. PubMed ID: 37865800
[TBL] [Abstract][Full Text] [Related]
8. Immunologic Signatures across Molecular Subtypes and Potential Biomarkers for Sub-Stratification in Endometrial Cancer.
Jiang F; Jiang S; Cao D; Mao M; Xiang Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675305
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC; Slomovitz B; Coleman RL; Pothuri B
Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
[TBL] [Abstract][Full Text] [Related]
10. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
11. HER2-positive endometrial cancer subtype carries poor prognosis.
Lapińska-Szumczyk S; Supernat A; Majewska H; Gulczyński J; Luczak A; Biernat W; Wydra D; Zaczek AJ
Clin Transl Sci; 2014 Dec; 7(6):482-8. PubMed ID: 25201050
[TBL] [Abstract][Full Text] [Related]
12. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.
Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q
BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic profiling identifies prognosis-related genes in the immune microenvironment of endometrial carcinoma.
Cheng P; Ma J; Zheng X; Zhou C; Chen X
Sci Rep; 2021 Jun; 11(1):12608. PubMed ID: 34131259
[TBL] [Abstract][Full Text] [Related]
14. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
15. A novel five-gene metabolism-related risk signature for predicting prognosis and immune infiltration in endometrial cancer: A TCGA data mining.
Huang H; Cai X; Lin J; Wu Q; Zhang K; Lin Y; Liu B; Lin J
Comput Biol Med; 2023 Mar; 155():106632. PubMed ID: 36805217
[TBL] [Abstract][Full Text] [Related]
16. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
[TBL] [Abstract][Full Text] [Related]
17. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
18. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
19. Prognostic classification of endometrial cancer using a molecular approach based on a twelve-gene NGS panel.
López-Reig R; Fernández-Serra A; Romero I; Zorrero C; Illueca C; García-Casado Z; Poveda A; López-Guerrero JA
Sci Rep; 2019 Dec; 9(1):18093. PubMed ID: 31792358
[TBL] [Abstract][Full Text] [Related]
20. p53 overexpression as a prognostic indicator in endometrial carcinoma.
Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]